Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2019 financial results ...
Preface In September 2018, I contributed to Vision and Value's blog article GR-MD-02: Keytruda's Partner . A long read, but a very good source of essential research if I do say so myself… More articles have come out since by both Vision and Value and First Genesis Consulting , whi...
Jounce Therapeutics (NASDAQ: JNCE ) is up 5% premarket on light volume in reaction to preclinical data on JTX-8064 presented at AACR in Atlanta. More news on: Jounce Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported data on JTX-8064, its first tumor-associated macrophage ...
Thinly traded micro cap Jounce Therapeutics ( JNCE +8% ) is up on average volume on the heels of new clinical data on lead candidate vopratelimab (JTX-2011) in patients with solid tumors. The results were presented at AACR in Atlanta. More news on: Jounce Therapeutics, Inc., Healthcare...
- Improved PFS and OS observed in patients treated with vopratelimab who have emergence of ICOS hi CD4 T cells compared to patients with ICOS lo CD4 T cells - - ICOS hi CD4 T cells demonstrate distinct, activated T effector cell characteristics - - Company to Host Investor Event a...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. China's Vice Premier Liu plans to travel to the U.S. next week in what could be ano...
Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...
Gainers: VivoPower International (NASDAQ: VVPR ) +52% . ENDRA Life Sciences (NASDAQ: NDRA ) +41% . Leap Therapeutics (NASDAQ: LPTX ) +31% . Stitch Fix (NASDAQ: SFIX ) +30% . Seelos Therapeutics (NASDAQ: SEEL ) +26% . Key Energy Services (NYSE: KEG ) +24% . Chaparral Energy (NYS...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...